Publication Date

6-4-2021

Journal

Baylor University Medical Center Proceedings

DOI

10.1080/08998280.2021.1925049

PMID

34211257

PMCID

PMC8182819

PubMedCentral® Posted Date

6-4-2021

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Keywords

colchicine, COVID-19, evidence-based, ivermectin, melatonin, outpatient therapy, SARS-CoV-2

Abstract

Misinformation and promotion of well-intended but disproved therapies for COVID-19 have plagued evidence-based shared decision-making throughout the COVID-19 pandemic. In times of crisis, clinicians may feel that their strong inclination to prescribe potentially harmful, unproven therapies on behalf of their patients is supported by beneficence. Clinicians should mindfully identify and avoid commission bias during this pandemic, especially as more data have accumulated to assist with clinically sound decision-making. We describe a more evidence-based approach to treatment of early outpatient COVID-19, stressing the availability of Food and Drug Administration emergency use authorization therapies and considering plausibly beneficial, nonprescription supplements that are generally regarded as safe.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.